Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study
Identifieur interne : 000821 ( Main/Corpus ); précédent : 000820; suivant : 000822Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study
Auteurs : L. Battistin ; P. G. Bardin ; F. Ferro-Milone ; C. Ravenna ; V. Toso ; G. ReboldiSource :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1999-01.
English descriptors
Abstract
Introduction ‐ A multicentre randomized double‐blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with l‐dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of α‐dihydroergocryptine (α‐DHEC) vs lisuride as an adjunct therapy to l‐dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern (Columbia University Rating Scale [CURS]), on disability (Northwestern University Disability Scale [NUDS]), and to evaluate the incidence of adverse events. Patients and methods ‐ Thirty‐two patients (18 males, 14 females with a mean age of 64.5 ± 1.5 SEM) were randomized to α‐dihydroergocryptine and 36 (16 males, 20 females with a mean age of 61.8 ± 1.4) to lisuride. The treatment lasted 3 months and the dosage was increased until it reached 60 mg/day of α‐dihydroergocryptine and 1.2 mg/day of lisuride, while the l‐dopa dosage was kept constant in both groups. Per protocol and intention to treat analyses were performed on response variables. Results ‐ The adjunctive treatment with the two dopamine agonists determined a significant improvement of PD symptoms in both groups. Alpha‐dihydroergocryptine showed a superior efficacy in reducing the clinical complications (P <0.01 by ANOVA). The number of patients complaining of adverse events was 8 out of 32 (25%) for α‐dihydroergocryptine and 24/36 (67%) for lisuride (P<0.05). Conclusion ‐ Alpha‐dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of l‐dopa therapy long term motor complications (UPDRS part IV) as well as in terms of the incidence and severity of adverse events.
Url:
DOI: 10.1111/j.1600-0404.1999.tb00655.x
Links to Exploration step
ISTEX:C43F00DBA19FD739789EFFD7F443760EC9D7E418Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study</title><author><name sortKey="Battistin, L" sort="Battistin, L" uniqKey="Battistin L" first="L." last="Battistin">L. Battistin</name><affiliation><mods:affiliation>Second Division of Neurology. University of Padua, Italy</mods:affiliation></affiliation></author><author><name sortKey="Bardin, P G" sort="Bardin, P G" uniqKey="Bardin P" first="P. G." last="Bardin">P. G. Bardin</name><affiliation><mods:affiliation>Division of Neurology. “Ca Foncello” Hospital. Treviso, Italy</mods:affiliation></affiliation></author><author><name sortKey="Ferro Ilone, F" sort="Ferro Ilone, F" uniqKey="Ferro Ilone F" first="F." last="Ferro-Milone">F. Ferro-Milone</name><affiliation><mods:affiliation>Division of Neurology. General Hospital, Vicenra. Italy</mods:affiliation></affiliation></author><author><name sortKey="Ravenna, C" sort="Ravenna, C" uniqKey="Ravenna C" first="C." last="Ravenna">C. Ravenna</name><affiliation><mods:affiliation>Division of Neurology. General Hospital. Mestre. Italy</mods:affiliation></affiliation></author><author><name sortKey="Toso, V" sort="Toso, V" uniqKey="Toso V" first="V." last="Toso">V. Toso</name><affiliation><mods:affiliation>Division of Neurology, General Hospital. Castelfranco Veneto, Italy</mods:affiliation></affiliation></author><author><name sortKey="Reboldi, G" sort="Reboldi, G" uniqKey="Reboldi G" first="G." last="Reboldi">G. Reboldi</name><affiliation><mods:affiliation>Di.M.I.S.E.M. University of Perugia. Perugia. Italy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C43F00DBA19FD739789EFFD7F443760EC9D7E418</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1111/j.1600-0404.1999.tb00655.x</idno><idno type="url">https://api.istex.fr/document/C43F00DBA19FD739789EFFD7F443760EC9D7E418/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000821</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study</title><author><name sortKey="Battistin, L" sort="Battistin, L" uniqKey="Battistin L" first="L." last="Battistin">L. Battistin</name><affiliation><mods:affiliation>Second Division of Neurology. University of Padua, Italy</mods:affiliation></affiliation></author><author><name sortKey="Bardin, P G" sort="Bardin, P G" uniqKey="Bardin P" first="P. G." last="Bardin">P. G. Bardin</name><affiliation><mods:affiliation>Division of Neurology. “Ca Foncello” Hospital. Treviso, Italy</mods:affiliation></affiliation></author><author><name sortKey="Ferro Ilone, F" sort="Ferro Ilone, F" uniqKey="Ferro Ilone F" first="F." last="Ferro-Milone">F. Ferro-Milone</name><affiliation><mods:affiliation>Division of Neurology. General Hospital, Vicenra. Italy</mods:affiliation></affiliation></author><author><name sortKey="Ravenna, C" sort="Ravenna, C" uniqKey="Ravenna C" first="C." last="Ravenna">C. Ravenna</name><affiliation><mods:affiliation>Division of Neurology. General Hospital. Mestre. Italy</mods:affiliation></affiliation></author><author><name sortKey="Toso, V" sort="Toso, V" uniqKey="Toso V" first="V." last="Toso">V. Toso</name><affiliation><mods:affiliation>Division of Neurology, General Hospital. Castelfranco Veneto, Italy</mods:affiliation></affiliation></author><author><name sortKey="Reboldi, G" sort="Reboldi, G" uniqKey="Reboldi G" first="G." last="Reboldi">G. Reboldi</name><affiliation><mods:affiliation>Di.M.I.S.E.M. University of Perugia. Perugia. Italy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1999-01">1999-01</date><biblScope unit="volume">99</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="36">36</biblScope><biblScope unit="page" to="42">42</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">C43F00DBA19FD739789EFFD7F443760EC9D7E418</idno><idno type="DOI">10.1111/j.1600-0404.1999.tb00655.x</idno><idno type="ArticleID">ANE36</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Iisuride</term><term>Parkinson's disease</term><term>dopamine aganists</term><term>l‐dopa</term><term>α‐dihydroergocryptine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Introduction ‐ A multicentre randomized double‐blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with l‐dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of α‐dihydroergocryptine (α‐DHEC) vs lisuride as an adjunct therapy to l‐dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern (Columbia University Rating Scale [CURS]), on disability (Northwestern University Disability Scale [NUDS]), and to evaluate the incidence of adverse events. Patients and methods ‐ Thirty‐two patients (18 males, 14 females with a mean age of 64.5 ± 1.5 SEM) were randomized to α‐dihydroergocryptine and 36 (16 males, 20 females with a mean age of 61.8 ± 1.4) to lisuride. The treatment lasted 3 months and the dosage was increased until it reached 60 mg/day of α‐dihydroergocryptine and 1.2 mg/day of lisuride, while the l‐dopa dosage was kept constant in both groups. Per protocol and intention to treat analyses were performed on response variables. Results ‐ The adjunctive treatment with the two dopamine agonists determined a significant improvement of PD symptoms in both groups. Alpha‐dihydroergocryptine showed a superior efficacy in reducing the clinical complications (P <0.01 by ANOVA). The number of patients complaining of adverse events was 8 out of 32 (25%) for α‐dihydroergocryptine and 24/36 (67%) for lisuride (P<0.05). Conclusion ‐ Alpha‐dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of l‐dopa therapy long term motor complications (UPDRS part IV) as well as in terms of the incidence and severity of adverse events.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>L. Battistin</name><affiliations><json:string>Second Division of Neurology. University of Padua, Italy</json:string></affiliations></json:item><json:item><name>P. G. Bardin</name><affiliations><json:string>Division of Neurology. “Ca Foncello” Hospital. Treviso, Italy</json:string></affiliations></json:item><json:item><name>F. Ferro‐Milone</name><affiliations><json:string>Division of Neurology. General Hospital, Vicenra. Italy</json:string></affiliations></json:item><json:item><name>C. Ravenna</name><affiliations><json:string>Division of Neurology. General Hospital. Mestre. Italy</json:string></affiliations></json:item><json:item><name>V. Toso</name><affiliations><json:string>Division of Neurology, General Hospital. Castelfranco Veneto, Italy</json:string></affiliations></json:item><json:item><name>G. Reboldi</name><affiliations><json:string>Di.M.I.S.E.M. University of Perugia. Perugia. Italy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>α‐dihydroergocryptine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Iisuride</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>l‐dopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine aganists</value></json:item></subject><articleId><json:string>ANE36</json:string></articleId><language><json:string>eng</json:string></language><abstract>Introduction ‐ A multicentre randomized double‐blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with l‐dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of α‐dihydroergocryptine (α‐DHEC) vs lisuride as an adjunct therapy to l‐dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern (Columbia University Rating Scale [CURS]), on disability (Northwestern University Disability Scale [NUDS]), and to evaluate the incidence of adverse events. Patients and methods ‐ Thirty‐two patients (18 males, 14 females with a mean age of 64.5 ± 1.5 SEM) were randomized to α‐dihydroergocryptine and 36 (16 males, 20 females with a mean age of 61.8 ± 1.4) to lisuride. The treatment lasted 3 months and the dosage was increased until it reached 60 mg/day of α‐dihydroergocryptine and 1.2 mg/day of lisuride, while the l‐dopa dosage was kept constant in both groups. Per protocol and intention to treat analyses were performed on response variables. Results ‐ The adjunctive treatment with the two dopamine agonists determined a significant improvement of PD symptoms in both groups. Alpha‐dihydroergocryptine showed a superior efficacy in reducing the clinical complications (P >0.01 by ANOVA). The number of patients complaining of adverse events was 8 out of 32 (25%) for α‐dihydroergocryptine and 24/36 (67%) for lisuride (P>0.05). Conclusion ‐ Alpha‐dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of l‐dopa therapy long term motor complications (UPDRS part IV) as well as in terms of the incidence and severity of adverse events.</abstract><qualityIndicators><score>7.237</score><pdfVersion>1.4</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1775</abstractCharCount><pdfWordCount>3737</pdfWordCount><pdfCharCount>26469</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>270</abstractWordCount></qualityIndicators><title>Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study</title><genre><json:string>article</json:string></genre><host><volume>99</volume><publisherId><json:string>ANE</json:string></publisherId><pages><total>7</total><last>42</last><first>36</first></pages><issn><json:string>0001-6314</json:string></issn><issue>1</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1600-0404</json:string></eissn><title>Acta Neurologica Scandinavica</title><doi><json:string>10.1111/(ISSN)1600-0404</json:string></doi></host><publicationDate>1999</publicationDate><copyrightDate>1999</copyrightDate><doi><json:string>10.1111/j.1600-0404.1999.tb00655.x</json:string></doi><id>C43F00DBA19FD739789EFFD7F443760EC9D7E418</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/C43F00DBA19FD739789EFFD7F443760EC9D7E418/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/C43F00DBA19FD739789EFFD7F443760EC9D7E418/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/C43F00DBA19FD739789EFFD7F443760EC9D7E418/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1999</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study</title><author><persName><forename type="first">L.</forename><surname>Battistin</surname></persName><affiliation>Second Division of Neurology. University of Padua, Italy</affiliation></author><author><persName><forename type="first">P. G.</forename><surname>Bardin</surname></persName><affiliation>Division of Neurology. “Ca Foncello” Hospital. Treviso, Italy</affiliation></author><author><persName><forename type="first">F.</forename><surname>Ferro‐Milone</surname></persName><affiliation>Division of Neurology. General Hospital, Vicenra. Italy</affiliation></author><author><persName><forename type="first">C.</forename><surname>Ravenna</surname></persName><affiliation>Division of Neurology. General Hospital. Mestre. Italy</affiliation></author><author><persName><forename type="first">V.</forename><surname>Toso</surname></persName><affiliation>Division of Neurology, General Hospital. Castelfranco Veneto, Italy</affiliation></author><author><persName><forename type="first">G.</forename><surname>Reboldi</surname></persName><note type="correspondence"><p>Correspondence: G Paolo Reboldi, Di.M.I.S.E.M. University of Perugia, Via E Dal Pozzo. 06126 Perugia. Italy</p></note><affiliation>Di.M.I.S.E.M. University of Perugia. Perugia. Italy</affiliation></author></analytic><monogr><title level="j">Acta Neurologica Scandinavica</title><idno type="pISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><idno type="DOI">10.1111/(ISSN)1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1999-01"></date><biblScope unit="volume">99</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="36">36</biblScope><biblScope unit="page" to="42">42</biblScope></imprint></monogr><idno type="istex">C43F00DBA19FD739789EFFD7F443760EC9D7E418</idno><idno type="DOI">10.1111/j.1600-0404.1999.tb00655.x</idno><idno type="ArticleID">ANE36</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1999</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Introduction ‐ A multicentre randomized double‐blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with l‐dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of α‐dihydroergocryptine (α‐DHEC) vs lisuride as an adjunct therapy to l‐dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern (Columbia University Rating Scale [CURS]), on disability (Northwestern University Disability Scale [NUDS]), and to evaluate the incidence of adverse events. Patients and methods ‐ Thirty‐two patients (18 males, 14 females with a mean age of 64.5 ± 1.5 SEM) were randomized to α‐dihydroergocryptine and 36 (16 males, 20 females with a mean age of 61.8 ± 1.4) to lisuride. The treatment lasted 3 months and the dosage was increased until it reached 60 mg/day of α‐dihydroergocryptine and 1.2 mg/day of lisuride, while the l‐dopa dosage was kept constant in both groups. Per protocol and intention to treat analyses were performed on response variables. Results ‐ The adjunctive treatment with the two dopamine agonists determined a significant improvement of PD symptoms in both groups. Alpha‐dihydroergocryptine showed a superior efficacy in reducing the clinical complications (P <0.01 by ANOVA). The number of patients complaining of adverse events was 8 out of 32 (25%) for α‐dihydroergocryptine and 24/36 (67%) for lisuride (P<0.05). Conclusion ‐ Alpha‐dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of l‐dopa therapy long term motor complications (UPDRS part IV) as well as in terms of the incidence and severity of adverse events.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>α‐dihydroergocryptine</term></item><item><term>Iisuride</term></item><item><term>Parkinson's disease</term></item><item><term>l‐dopa</term></item><item><term>dopamine aganists</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1999-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/C43F00DBA19FD739789EFFD7F443760EC9D7E418/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0404</doi><issn type="print">0001-6314</issn><issn type="electronic">1600-0404</issn><idGroup><id type="product" value="ANE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ACTA NEUROLOGICA SCANDINAVICA">Acta Neurologica Scandinavica</title></titleGroup></publicationMeta><publicationMeta level="part" position="01001"><doi origin="wiley">10.1111/ane.1999.99.issue-1</doi><numberingGroup><numbering type="journalVolume" number="99">99</numbering><numbering type="journalIssue" number="1">1</numbering></numberingGroup><coverDate startDate="1999-01">January 1999</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0003600" status="forIssue"><doi origin="wiley">10.1111/j.1600-0404.1999.tb00655.x</doi><idGroup><id type="unit" value="ANE36"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><eventGroup><event type="firstOnline" date="2009-01-29"></event><event type="publishedOnlineFinalForm" date="2009-01-29"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-10"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-15"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="36">36</numbering><numbering type="pageLast" number="42">42</numbering></numberingGroup><correspondenceTo>G Paolo Reboldi, Di.M.I.S.E.M. University of Perugia, Via E Dal Pozzo. 06126 Perugia. Italy</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANE.ANE36.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Accepted for publication August 10, 1998</unparsedEditorialHistory><countGroup><count type="referenceTotal" number="40"></count><count type="linksCrossRef" number="7"></count></countGroup><titleGroup><title type="main">Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>L.</givenNames><familyName>Battistin</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>P. G.</givenNames><familyName>Bardin</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a3"><personName><givenNames>F.</givenNames><familyName>Ferro‐Milone</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a4"><personName><givenNames>C.</givenNames><familyName>Ravenna</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a5"><personName><givenNames>V.</givenNames><familyName>Toso</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a6" corresponding="yes"><personName><givenNames>G.</givenNames><familyName>Reboldi</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="IT"><unparsedAffiliation>Second Division of Neurology. University of Padua, Italy</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="IT"><unparsedAffiliation>Division of Neurology. “Ca Foncello” Hospital. Treviso, Italy</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="IT"><unparsedAffiliation>Division of Neurology. General Hospital, Vicenra. Italy</unparsedAffiliation></affiliation><affiliation xml:id="a4" countryCode="IT"><unparsedAffiliation>Division of Neurology. General Hospital. Mestre. Italy</unparsedAffiliation></affiliation><affiliation xml:id="a5" countryCode="IT"><unparsedAffiliation>Division of Neurology, General Hospital. Castelfranco Veneto, Italy</unparsedAffiliation></affiliation><affiliation xml:id="a6"><unparsedAffiliation>Di.M.I.S.E.M. University of Perugia. Perugia. Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">α‐dihydroergocryptine</keyword><keyword xml:id="k2">Iisuride</keyword><keyword xml:id="k3">Parkinson's disease</keyword><keyword xml:id="k4"><sc>l</sc>‐dopa</keyword><keyword xml:id="k5">dopamine aganists</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p> <i>Introduction</i> ‐ A multicentre randomized double‐blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with <sc>l</sc>‐dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of α‐dihydroergocryptine (α‐DHEC) vs lisuride as an adjunct therapy to <sc>l</sc>‐dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern (Columbia University Rating Scale [CURS]), on disability (Northwestern University Disability Scale [NUDS]), and to evaluate the incidence of adverse events. <i>Patients and methods ‐</i> Thirty‐two patients (18 males, 14 females with a mean age of 64.5 ± 1.5 SEM) were randomized to α‐dihydroergocryptine and 36 (16 males, 20 females with a mean age of 61.8 ± 1.4) to lisuride. The treatment lasted 3 months and the dosage was increased until it reached 60 mg/day of α‐dihydroergocryptine and 1.2 mg/day of lisuride, while the <sc>l</sc>‐dopa dosage was kept constant in both groups. Per protocol and intention to treat analyses were performed on response variables. <i>Results ‐</i> The adjunctive treatment with the two dopamine agonists determined a significant improvement of PD symptoms in both groups. Alpha‐dihydroergocryptine showed a superior efficacy in reducing the clinical complications (<i>P</i> <0.01 by ANOVA). The number of patients complaining of adverse events was 8 out of 32 (25%) for α‐dihydroergocryptine and 24/36 (67%) for lisuride (<i>P</i><0.05). <i>Conclusion</i> ‐ Alpha‐dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of <sc>l</sc>‐dopa therapy long term motor complications (UPDRS part IV) as well as in terms of the incidence and severity of adverse events.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study</title></titleInfo><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Battistin</namePart><affiliation>Second Division of Neurology. University of Padua, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P. G.</namePart><namePart type="family">Bardin</namePart><affiliation>Division of Neurology. “Ca Foncello” Hospital. Treviso, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Ferro‐Milone</namePart><affiliation>Division of Neurology. General Hospital, Vicenra. Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Ravenna</namePart><affiliation>Division of Neurology. General Hospital. Mestre. Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V.</namePart><namePart type="family">Toso</namePart><affiliation>Division of Neurology, General Hospital. Castelfranco Veneto, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Reboldi</namePart><affiliation>Di.M.I.S.E.M. University of Perugia. Perugia. Italy</affiliation><description>Correspondence: G Paolo Reboldi, Di.M.I.S.E.M. University of Perugia, Via E Dal Pozzo. 06126 Perugia. Italy</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1999-01</dateIssued><edition>Accepted for publication August 10, 1998</edition><copyrightDate encoding="w3cdtf">1999</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">40</extent></physicalDescription><abstract lang="en">Introduction ‐ A multicentre randomized double‐blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with l‐dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of α‐dihydroergocryptine (α‐DHEC) vs lisuride as an adjunct therapy to l‐dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern (Columbia University Rating Scale [CURS]), on disability (Northwestern University Disability Scale [NUDS]), and to evaluate the incidence of adverse events. Patients and methods ‐ Thirty‐two patients (18 males, 14 females with a mean age of 64.5 ± 1.5 SEM) were randomized to α‐dihydroergocryptine and 36 (16 males, 20 females with a mean age of 61.8 ± 1.4) to lisuride. The treatment lasted 3 months and the dosage was increased until it reached 60 mg/day of α‐dihydroergocryptine and 1.2 mg/day of lisuride, while the l‐dopa dosage was kept constant in both groups. Per protocol and intention to treat analyses were performed on response variables. Results ‐ The adjunctive treatment with the two dopamine agonists determined a significant improvement of PD symptoms in both groups. Alpha‐dihydroergocryptine showed a superior efficacy in reducing the clinical complications (P <0.01 by ANOVA). The number of patients complaining of adverse events was 8 out of 32 (25%) for α‐dihydroergocryptine and 24/36 (67%) for lisuride (P<0.05). Conclusion ‐ Alpha‐dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of l‐dopa therapy long term motor complications (UPDRS part IV) as well as in terms of the incidence and severity of adverse events.</abstract><subject lang="en"><genre>Keywords</genre><topic>α‐dihydroergocryptine</topic><topic>Iisuride</topic><topic>Parkinson's disease</topic><topic>l‐dopa</topic><topic>dopamine aganists</topic></subject><relatedItem type="host"><titleInfo><title>Acta Neurologica Scandinavica</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0001-6314</identifier><identifier type="eISSN">1600-0404</identifier><identifier type="DOI">10.1111/(ISSN)1600-0404</identifier><identifier type="PublisherID">ANE</identifier><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>36</start><end>42</end><total>7</total></extent></part></relatedItem><identifier type="istex">C43F00DBA19FD739789EFFD7F443760EC9D7E418</identifier><identifier type="DOI">10.1111/j.1600-0404.1999.tb00655.x</identifier><identifier type="ArticleID">ANE36</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000821 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000821 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:C43F00DBA19FD739789EFFD7F443760EC9D7E418
|texte= Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study
}}
| This area was generated with Dilib version V0.6.23. |  |